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A kinin-forming-enzyme in human skin extract was 
further purified by successive column chromatography 
on DEAE-cellulose, Hydroxylapatite-cellulose and Seph-
arose-4B. By these procedures, 2. 7 mg of purified enzyme 
was obtained from 10 gm of original skin. The purified 
material was homogeneous as ascertained by cellulose 
acetate membrane electrophoresis, sodium dodecyl sul-
fate polyacrylamide gel disc electrophoresis and ultra-
centrifugation. It had an S2o.w value of 4.3 and an appar-
ent molecular weight of 104,000 as measured by gel 
filtration on Sephadex G-200. The purified enzyme was 
comparatively beat-stable, but was unstable below pH 
values of 5 and above pH 9. It possessed arginine or 
lysine esterolytic activity, but not tyrosine or trypto-
phane esterolytic activity and denatured proteolytic ac-
tivity. This enzyme was not affected by metal ion, cy-
stein, glutatbion or p-chloromercuribenzoate, but was 
strongly inhibited by a-N-p-tosyl-L-lysine chloromethyl 
ketone or soybean-trypsin inhibitor. It was also inhibited 
by a1-antitryp in, but not by a2-macroglobulin. This 
enzyme was confirmed to be immunologically distinct 
from human plasma, urinary or pancreas kallikrein. 
It has been reported that kinin-forming (KF) activity is 
produced in human eccrine sweat by heating (1]. Noted also 
was that kinin-like activity in skin perfusate is 5 times higher 
during heating as compared to when kept cool. Fraki, Jansen, 
and Hopsu-Havu (2) fractionated human sweat and found Bz-
Arg-OEt hydrolyzing enzyme whjch increased vascular perme-
ability when injected intradermally. On the contrary, Frewin, 
McConnel, and Downey (3] were not a ble to detect kinins in 
sweat, but succeeded in fmding kininogenase activity in some 
sweat samples. Many aspects of the kallikrein-kinjn system in 
human skin have yet to be clarified. In preliminary reports 
( 4,5], t he authors indicated that the kinin-forming-enzyme 
(KFE) which is suggestive of a kallikrein-like enzyme, could be 
extracted from normal human skin and that for optimal extrac-
tion of thls enzyme a salt concentration higher than 1.5 M in 
the extraction buffer was required. The authors also fo\md an 
inhibitor of this enzyme in the extract with buffer alone. In the 
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Abbreviations: 
A TEe: a-N-acetyl-L-tyrosine ethyl ester 
A TrEe: a-N-acetyl-L-tryptophane ethyl ester 
BAEe: a-N-p-benzoyi-L-arginine ethyl ester 
KF: kinin-forming 
K.FE: kinin-forming-enzyme 
PAGE: polyacrylamide gel disc electrophoresis 
PCMB: p-chloromercuribenzoate 
SBTI: soyb an-trypsin inhibitor 
SDS: sodium dodecyl sulfate 
TAMe: a -N-p-tosyl-L-arginine methyl ester 
TLCK: a-N-p-tosyl-L-Iysine chloromethyl ketone 
TLMe: a-N-p-tosyl-L-lysine methyl ester 
TPCK: a-N-p-tosyl-L-phenylalanine chJoromethyl ketone 
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present study, the authors reported on their success in KFE 
purification by successive column chromatography together 
with some of its physical characteristics. 
MATERIALS AND METHODS 
The Following Commercial Preparations Were Used 
ephadex G-200 (Pharmacia), DEAE-cellulose (Brown, 0.85 mEq/ g, 
Lot No. 2256), Hydroxylapatite (Seikagaku Kogyo Co., Ltd.), Cellulose 
Mikrokristallin (Merck), Sepharose-4B (Pharmacia), a-N-p-Tosyi-L-
arginine methyl ester (TAMe) ( igma) , a-N-p-Benzoyi-L-arginine ethyl 
ester (BAEe)( igma), a-N-p-Tosyi-L-lysine methyl ester 
(TLMe)(Nakarai Chern. Co., Ltd.), a-N-Acetyi-L-tyrosine ethyl ester 
(ATEe)(Merck), a-N-Acetyl-L-tryptophane ethyl ester 
(A TrEe)( igma), Casein nach Harnma.rsten (Merck), Fibrinogen (Wako 
Pure Chern. Co., Ltd.) , L-Cystein (Wako Pure Chern. Co., Ltd.), Glu-
tathion (Wako Pure Chern. Co., Ltd.), p-chloromercuribenzoate 
(PCMB)(Wako Pure Chern. Co., Ltd.), a-N-p-Tosyl-L-lysine chloro-
melhyl ketone (TLCK)(Sigma), a-N-p-Tosyl-L-phenylalanine chloro-
methyl ketone (TPCK)( eikagaku Kogyo Co., Ltd.), Soybean-trypsin 
inhibitor (SBTI)(Boehringer), Bradykinin (Sand Pharm. Co., Ltd.), 
Carboxypeptidase A (from bovine pancreas, Wako Pure Chern. Co., 
Ltd.). 
Extraction of KFE from Human Skin 
arnples of human skin were obtained from patients who had under-
gone mammectomy. The skin was removed and cleaned thoroughly 
free of subcutaneous fat, washed in cold deionized water and frozen at 
-20°C for 1-4 days. The frozen skin was minced with scissors and 
homogenized with Virtis-Homogenizer (Virtis Co., Ltd.) in 10 volumes 
(w/ v) of 0.1 M phosphate buffer at pH 7.4 containing 1.5 M KCI. The 
homogenate was maintained at 0°C overnight and then centrifugated 
at 4°C for 30 min at 15000 x g. The supernatant was filtered through 
glass fiber and dialyzed for 3 days at 4°C with 0.1 M phosphate buffer 
at pH 7.4 which was changed 4 times daily. The dialyzed filtrate was 
concentrated to one-tenth of its original volume by ultrafiltration. The 
concentrated sample was identified as HSE in this study. 
Evaluation of KF Activity 
Human plasma kininogen was prepared as described by Jonasson 
and Becker [6]. Plasma was heated at 61 oc for 2 hr and then acidified 
to pH 1.5 with HCI to destroy the plasma kallikrein system, inactivate 
kininase and prevent spontaneous formation of bradykinin. Partially 
purified kininogen-I was prepared by the method of Jacobsen and Kriz 
[7]. Kininogen-! was also heated at 61°C for 2 hr and then acidified to 
pH 1.5 with HCI by the method of Jonasson and Becker [6]. The ability 
of samples to generate kinin from kininogen-I was tested by bioassay 
using isolated rat uterus suspended in a 2 ml organ bath in oxygenerated 
de Jalon solution (28°C) containing atropine sulfate (10 7M). Various 
volume of the sample or varying degrees of sample-compound-mixture 
were incubated with 0.1 ml of kininogen-I for 2 min at 37°C and the 
incubated mixture was tested on rat uterus. Suitable dilutions of this 
mixture were prepared with de Jalon solution containing atropine 
sulfate at a concentration of 10 7M . Quantitative values were obtained 
by comparing the amplitude of contraction of the experimental sample 
with those produced by known quantities of synthetic bradykinin. In 
the present study, in order to reconfirm that uterus contracting activity 
in the sample-kininogen-mixture is due to the appearance of kinin, the 
inhibitory effect of carboxypeptidase A for uterus contracting activity 
was examined and it was confl.l1lled that the uterus contracting activity 
which is appropriate to 20 ng of kinin activity could be completely 
extinguished by incubating with 5.3 x 10-J units of carboxypeptidase A 
at pH 5.2 and 30°C for 30 min. 
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E timation of Esterolytic and Proteolytic Activities and Protein 
Concentration of Samples 
The esterolytic activity of samples was measured by Hestrin's 
method (8] as modified by Roberts (9]. The proteolytic activity of 
samples was determined by Lowry's method (10) as described in an 
earlier report [ ll]. The fmal concentration of synthetic esters used in 
the present study was 10 mM and that of denatured protein was 2%. 
The protein concentration was also estimated according to the method 
of Lowry et al (10] using bovine serum albumin (Merck) as reference 
protein. 
Electrophoretic Technique 
odium dodecyl sulfate (SDS) polyacrylamide gel disc electropho-
resis (PAGE) was carried out by the method of Weber and Osborn (12) 
using 7.5% gel with 1.0% SDS and 8 M urea. Electrophoresis was 
performed at 8 MA;gel for 4 hr. Gel was stained for 2 hr with 2% 
Coomassie brilliant blue and destained electrophoretically. 
Ultracentrifugal Analysis 
Purified KFE was dialyzed against 0.1 M phosphate buffer at pH 7.4 
and then subjected to ultracentrifugal analysis in a Hitachi Analytical 
Ultracentrifuge at a protein concentration of 0.5%. 
Preparation of Human Plasma Kallikrein 
Human plasma kallikrein activated by acetone treatment was pre-
pared by the method of Tsutsumi (13) as follows: isoelectric precipita-
tion at pH 5.3, treatment of the euglobulin fraction with ethylenedia-
mine-tetraacetic acid at pH 4.8, ammonium sulfate fraction at 0.3 
saturation, adsorption and elution on Ca phosphate gel, and linear 
gradient elution from DEAE-Sephadex column. One mg of human 
plasma kallikrein activated with acetone hydrolyzed 380 1-1moles of 
TAMe in O.l M phosphate buffer at pH 7.4 in 1 hr at 37"C. Human 
urinary kallikrein which was kindly supplied by Dr. H . Sumi, Michael 
Reese Blood Center, Chicago, possessed a specific activity of 115 
1-1moles/hr/mg. Hog pancreas kallikrein purchased from Bayer Co., Ltd. 
possessed a specific activity of 13.8 J.tmoles/hr/mg. Human pancreas 
kallikrein was kindly supplied by Green Cross Co., Ltd., Osaka. 
Preparation of Human Plasma Proteinase Inhibitor 
a2-macroglobulin (a2-M) and at-antitrypsin (al-At) were prepared 
as described in previous reports ( 14,15]. The concentration of protein 
in a2-M was 0.3 mg/ rnl and the specific activity was 15.5 units/mg. The 
concentration in al-At was 1.1 mg/ rnl with a specific activity of 3.5 
units/mg. One unit of a2-M or a1-At was expressed as the amount of 
inhibitor required to completely inhibit one casein unit of trypsin which 
was defined as the amount of enzyme releasing 60 l-IS of acid-soluble 
tyrosine in 15 min on incubation at 37"C. 
Preparation of Antisera 
Two mg of purified KFE was dissolved in 1.0 ml of physiologic saline, 
mixed with an equal volume of complete Freund's adjuvant and injected 
into toe pads of a rabbit. After 4 weeks the rabbit received as a booster 
dose, the same amount of KFE injected subcutaneously into the back. 
After 2 weeks, a blood sample was drawn from the rabbit and incubated 
at 37"C for 3 hr and at 4"C for 18 hr before separating the serum by 
centrifugation at 2500 xg. Antiserum against purified human plasma 
kallikrein was also prepared by the same method as that of KFE. 
Immunodiffu.9ion in Agarose 
Double-diffusion analysis (Ouchterlony method) (16) was performed 
at room temperature for 24 hr in 1.0% agarose (Behringwerke) in 
veronal buffer<- 0.05, pH 8.6) containing 0.05% NaNa. 
RESULTS 
Purification of KFE 
KFE was purified further by successive column chromatog-
raphy on DEAE-cellulose, Hydroxylapatite-cellulose and Seph-
arose-4B. All purification procedures were performed at 4"C. 
Step 1. DEAE-cellulose column chromatography: As de-
scribed in a previous report [5), KFE was eluted in the fractions 
of the second protein peak with Sephadex G-200 gel filtration . 
KFE fractions were collected and dialyzed overnight against 
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0.01 M phosphate buffer at pH 7.4 containing 0.5 M NaCl at 
4°C. The dialyzed solution was chromatographed on a DEAE-
cellulose column (1.9 x 8 em) which had been equilibrated with 
0.01 M phosphate buffer at pH 7.4 containing 0.05 M NaCI. After 
washing with 100 mJ of the same buffer, the column was eluted 
with a linear gradient formed from 100 rnJ of equilibration 
buffer and 100 rnJ of 0.01 M phosphate buffer at pH 7.4 contain-
ing 0.3 M NaCl, at a flow rate of25 rnJ per hr (5 rnJ per tube). As 
shown in Fig 1, KFE was eluted in nonadsorbed fractions No. 
5-15. These KFE fractions were collected and stored at 0°C 
until use for further purification. 
Step 2. Hydroxylapatite-cellulose column chromatography: 
Hydroxylapatite-cellulose was prepared by mixing Hydroxyl-
apatite and Cellulose Mikrokristallin at equal weight volumes 
in 0.01 M phosphate buffer at pH 7.4. KFE fractions obtained 
from DEAE-cellulose column were dialyzed overnight against 
0.01 M phosphate buffer at pH 7.4 at 4 °C. The dialyzed solution 
was chromatographed on a Hydroxylapatite-cellulose column 
(2.0 X 8.0 em) which had been equilibrated with 0.01 M phos-
phate buffer at pH 7.4. KFE was eluted with a linear gradient 
formed from 75 mJ of equilibration buffer and 75 mJ of 0.2 M 
phosphate buffer at pH 7.4, at a flow rate of 30 rnJ per hr (5 m1 
per tube). As shown in Fig 2, one main peak with KFE activity 
was eluted in fractions Nos. 24-31. They were combined, con-
centrated to 4 rnJ by ultrafiltration, and dialyzed against 0.05 M 
phosphate buffer at pH 7.4. 
Step 3. Sepharose-48 gel Filtration: Partially purified KFE 
obtained from Step 2 (about 4 ml) was subjected to gel filtration 
on Sepharose-4B (2.0 x 65 em) which had been equilibrated 
with 0.05 M phosphate buffer at pH 7.4. The column was eluted 
with the same buffer at a flow rate of 15 rnJ per hr. Fractions of 
5 ml were collected. As shown in Fig 3, the protein was eluted 
as a single peak and the main part of the peak in tubes Nos. 24-
30 was pooled. The pooled sample was frozen at -20°C and 
stored until use. The overall purification and yield of KFE are 
summarized in Table I. A final yield of 2. 7 mg of purified 
preparation was obtained from 10 gm of original skin. The final 
product generated 229.63 ng of kinin from kininogen-I per mg 
of protein in de Jalon solution after incubation for 2 min at 
37°C. A part of KFE was lyophilized and stored until use as an 
antigen. 
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FIG 1. Chromatography of KFE on DEAE-cellulose column. See 
text for details of column chromatography. An aliquot of 0.05 ml of 
each fraction was incubated with 0.1 rnl of kininogen-1 at 37"C for 2 
min. The incubated mixture was diluted with de Jalon solution and 
tested on rat uterus. (--) absorbance at 750 m1-1. (x--x) ng of kinin 
generated. 
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FIG 2. Chromatography of KFE on a Hydroxylapatite-cellulose col-
umn. ee text for details of column chromatography. To detect the KF 
activity in each fraction, 0.1 ml of each fraction was incubated with 0.1 
mJ of kininogen-! at37°C for 2 min. After suitable dilution, the reaction 
mixture was tested on rat uterus. (--) absorbance at 750 m11. 
{X--X) ng of kinin generated. 
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FIG 3. Gel filtration of partially purified KFE on a column of Seph-
arose-4B . See text for details of column chromatography. KF activities 
in each fraction were determined as described in Fig 2. (--) absorb-
ance at 750 m11. (x--x) ng of kinin generated. 
Homogeneity of KFE 
During electrophoresis on cellulose acetate at 4 oc in verona! 
buffer at pH 8.6 and ionic strength 0.05, KFE had the same 
mobility as ,8-globulin in normal serum. Its homogeneity was 
also demonstrated by SDS-PAGE and ultrafl.ltration (Fig 4 and 
5) . Its sedimentation coefficient, 820 ... was 4.3. 
Heat and pH-stability of KFE: 
The activity of the KFE was unstable by incubation for 30 
min at 65°C and was completely inactivated at 75°C. In order 
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to examine the pH-stability of KFE, aliquots of 0.4 ml of 
purified KFE (with activity sufficient to generate 7.2 ng of kinin 
after incubation with kininogen-! for 2 min at 37°C) were 
adjusted to various pH values with 0.15 M HCl or NaOH and 
kept at 4 oc for 12 hr, after which they were readjusted to pH 
7.4. Following suitable dilutions, KF activity was assayed on rat 
uterus. As shown in Fig 6, the activity of the KFE progressively 
diminished below the pH value of 5.0 and above pH 9.0. 
Sub trate pecific Studies 
To examine the esterolytic or proteolytic activity of KFE, 
enzyme solution was concentrated to one-tenth of its original 
volume by ultrafl.ltration. Table II shows that the purified KFE 
possesses a little esterolytic activity for TAMe, BAEe and 
TLMe which are representative substrates for kallikrein, plas-
min and trypsin, but A TEe and A TrEe which are representative 
substrates for chymotrypsin can not be hydrolyzed by it. Casein 
or fibrionogen also could not be digested by KFE. In the present 
study, the esterolytic and biologic activities of KFE were com-
pared with those of human plasma kallikrein, human urinary 
kallikrein or hog pancreas kallikrein. As shown in Table III, 
biologic-esterolytic activity ratios between human plasma kal-
likrein, human urinary kallikrein and hog pancreas kallikrein 
were almo t the same. The ratio of KFE, on the contrary, was 
remarkably higher. 
Effects of various compounds upon KFE 
Compounds suspected of producing possible inhibition or 
activation of KFE were incubated with the enzyme preparation 
TABLE I. Summary of the purification of KFE 
Total Total protem pecific Recovery in activity activity 
(ng) (mg) (ng/ mg) total act. (%) 
HSE 2560 210 12.19 100 
ephadex G-200 2200 75 29.33 85.9 
DEAE-cellulose 1750 42 41.67 68.4 
Hydroxylaptite 730 3.5 208.57 28.5 
Sepharose-4B 620 2.7 229.63 24.2 
FIG 4. D -PAGE of purified KFE. Purified KFE (Ca. 50 11g pro-
tein) was subjected to electrophoresis in a 1.0 x 10 em polyacrylamide 
gel column. ample diluted consisted of 8 M urea, 1% SDS and 0.01 M 
phosphate buffer at pH 7.2. 
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FJG 5. Ultracentrifugal analysis of purified KFE. The photograph 
was taken 60 min after reaching the full speed of 60,000 rpm at 5°C. 
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FIG 6. PH-stability of purified KFE. See text for details of experi-
ment. 
before addition to the reaction solution containing kininogen-I. 
With the exception of inorganic salt solutions, all addends were 
adjusted to pH 7-8 before addition to the enzyme. At a reaction 
solution concentration of 6 X 10- • M, FeC12 or HgC12 failed to 
demonstrate any effects. Cystein or glutathion, at 3.5 X w-a M 
were also unaffected. The addition of PCMB likewise did not 
affect the KFE. TLCK, at 3 X w-a M produced about 60% 
inhibition, but TPCK, at the same concentration, failed to 
demonstrate an effect upon KFE. One hundred p.g of SBTI in 
the reaction mixture inhibited 70% of KFE. Prior to these tests, 
it had been confirmed that none of the compounds at any 
concentration had effects on the contraction of rat uterus by 
standard bradykinin. 
Effect of Human Plasma Protease Inhibitors 
lt has been reported that human skin extract contains 2 
protease inhibitors identified as a2-M and al-At by immuno-
diffusion method [16). In a preliminary report, the authors also 
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TABLE II. Estrolytic and proteolytic activity of KFE 
Subslrales Eslerolytic or proteolytic activity 
Synthetic substrates, J.UTIOles/min/mg 
TAMe 0.35 
BAEe 0.27 
TLMe 0.39 
ATEe 0 
ATrEe 0 
Denatured proteins 
Casein 0 
Fibrinogen 0 
To measure the esterolytic and proteolytic activities of KFE purified 
KFE solution was concentrated to one tenth of its original volume by 
ultrafiltration. The concentration of protein in the concentrated KFE 
solution was 0.8 mg/ml. To measure the esterolytic activity, 0.5 rn1 of 
KFE solution was added to a test tube containing 0.5 ml of 20 rnM 
synthetic ester, after which it was incubated for 1 hr at 37°C. To 
measure the proteolytic activity of KFE, 0.5 ml of KFE solution was 
added to a test tube containing 0.25 ml of phosphate buffer (0.1 M, pH 
7.4) and 0.25 ml of8% Casein or Fibrinogen, after which it was incubated 
for I hr at 37°C. 
TABLE III. Biologic and esterolytic activity of various preparations 
o(KFE 
Biologic activ- Eslerolytic activity Biologic Enzyme preparation (TAMe) (Jillloles/ ratio ity (ng/mg) min/ mg) Eslerolytic 
Human plasma kal- 476 6.38 74.6 
likrein 
Human urinary kal- 126 1.87 67.4 
likrein 
Hog pancreas kalli- 16 0.23 69.6 
krein 
PKF enzyme 229 0.35 654.3 
70 
60· 
50 
..... 
:; 30· 
1 0 
1 5 30 45 60 
Incubation time (min) 
FIG 7. Inhibitory effects of a2-M or at-At against KFE. Aliquots of 
0.2 ml of a2-M or al-At were added to 0.2 ml of KFE (with activity 
sufficient to generate 3.6 ng of kinin after incubation with kininogen-I 
for 2 min at 37°C). After incubation for various time intervals, 0.1 rnl 
of kininogen-I was added and the mixtures were reincubated for 2 min 
at 37°C. After suitable dilution, the reaction mixture was tested on rat 
uterus. (e----e) % inhibition of KFE by a2-M. (0--0) % inhibition 
of KFE by al -At. 
stated that the buffer extract from human skin contained an 
inhibitor against KFE [5). In the present study, for the purpose 
of studying inhibitory effects, purified a2-M or al-At were 
incubated with KFE for various intervals at 37°C before addi-
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FIG 8. A, Immunodiffusion reactions of rabbit anti-KFE against 
various kallikrein. Center well (AS): undiluted anti-KFE (0.2 ml), 
Peripheral wells: !-purified KFE (10 ~/0.02 ml), 2-purified KFE (5 
~J.g/0.02 ml) , 3-human plasma kallikrein (10 Jlg/ 0.02 ml), 4-human uri-
nary kallikrein (10 J!g/0.02 ml), 5-human pancreas kallikrein (10 Jlg/0.02 
ml), 6-hog pancreas kallikrein (10 Jlg/0.02 ml) . B, Immunodiffusion 
reactions of rabbit anti-human plasma kallikrein against various sam-
ples. Center well (AS): undiluted antihuman plasma kallikrein (0.2 ml) , 
Peripheral wells: !-purified human plasma kallikrein (10 Jlg/0.02 ml), 
2-purified human plasma kallikrein (5 Jlg/0.02 ml), 3-diluted human 
serum (1:15/0.02 ml), 4-diluted human serum (1:30/0.02 ml), 5-purified 
KFE (10 llg/0.02 ml), 6-purified KFE (5 Jlg/0.02 ml) . 
tion to the reaction solution containing kininogen-!. As shown 
in Fig. 7, the inhibitory rate of a-At for KFE increased with the 
length of incubation time, reaching a plateau in 45 min. On the 
other hand, no inhibitory effects induced by a2-M could be 
detected. 
Immunological Identification 
When purified KFE or human plasma kallikrein was injected 
into a rabbit, no precipitating antibody was found on Day 28. A 
booster injection on this day gave an appreciate increase in 
antibody titer on Day 42. The antiserum used in this study was 
obtained from specimens of massive hemorrhage on Day 42. In 
the present study, to elucidate the identity of KFE with human 
plasma, urinary or pancreas kallikrein, immun_ologic ch~ac~er­
ization of KFE was investigated by double unmunodiffus10n 
method. As shown in Fig 8-A, rabbit antiserum against ~FE 
formed a single immunoprecipitin line with the KFE, but failed 
to react with human plasma, urinary, pancreas or hog pancreas 
kallikrein. On the other hand, as shown in Fig 8-B, rabbit 
antiserum against purified human plasma kallikrein_ fo':"ed a 
single immunoprecipitin line with human plasma kallikrem and 
diluted serum but failed to react with the KFE. These results 
indicate that KFE in human skin is immunologically distinct 
from human plasma, urinary or pancreas kallikrein. 
DISCUSSION 
Since Frey and Kaut discovered in urine hypotensive peptide 
which was later renamed kallikrein, and subsequently an enor-
mous amount of literature has been accumulated on the extrac-
tion, purification and characterization of kallikrein originating 
in human plasma [18], urine [19], saliva [20], sweat [3] and 
pancreas [21]. In 1958, Lewis [22] showed that if a 2_ M KS<?N-
extract of rat skin was incubated with a pseudoglobulin solut10n, 
a smooth-muscle stimulating activity appeared in the inc~ba­
tion mixture. The purification of the KFE from human skin or 
its characterization, however, had yet to be achieved. In the 
present study, KFE was fLrSt purified by successive column 
chromatography on DEAE-cellulose, Hydroxylapatite-cellulose 
and Sepharose-4B, and some of its characteristics were exam-
ined. The purified material appeared homogeneous on cellulose 
acetate membrane electrophoresis, SDS-PAGE and ultracen-
trifugation. Its S20.w was 4.3 and its molecular weight was 
determined as 104,000 by gel flltration on Sephadex G-200. This 
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KFE was comparatively stable to heating up to 65°C and its 
optimum pH was between 6 to 8. Although KFE could hydro-
lyze such representative synthetic esters of trypsin like enzyme, 
no proteolytic activity could be detected. It was also confirmed 
that KFE was not affected by metal ion (Fe++, Hg++), and the 
addition of cystein, glutathion and PCMB to the reaction 
mixture did not induce any activation or inhibition. On the 
other hand, the addition of TLCK or SBTI which are inhibitors 
of glandular kallikrein, strongly inhibited KFE. These results 
raise the possibility that KFE purified from human skin extract 
may be tissue kallikrein. In 1971, Tsutsumi [13] reported that 
the molecular weight of purified human plasma kallikrein was 
110,000. Moriya, Pierce, and Webster [21] also reported that 
the molecular weight of human urinary kallikrein was 40,500 
and that of human pancreas kallikrein was 31,200. In the present 
study, it was confirmed that the molecular weight of KFE from 
human skin was 104,000 which closely approximates that of 
human plasma kallikrein. These facts raise another possibility 
that KFE may be the same enzyme as plasma kallikrein. 
On the other hand, as shown in Table III, it was confirmed 
that contrary to the fact that biologic-esterolytic activity ratios 
between human plasma kallikrein and human urinary kallikrein 
and hog pancreas kallikrein were the same, that of KFE from 
human skin was remarkably higher. From this result, it was 
surmised that the mechanism of degradation of kininogen by 
KFE from human skin might be different from that of human 
plasma kallikrein, human urinary kallikrein or hog pancreas 
kallikrein. Moreover, in the present study, the inhibitory effects 
of a2-M or al-At on KFE were examined. As shown in Fig 8, 
al-At gradually inhibited KFE, but it could not be inhibited by 
a2-M. In 1970 Harpel (23] reported that the esterolytic activity 
of plasma kallikrein was elevated in the a2-M fractions when 
the incubated mixture of plasma kallikrein and a2-M were 
subjected to Sephadex G-200 gel flltration, and that kallikrein 
when bound with a2-M had no KF activity. The authors [24] 
also confirmed that almost all of the kallikrein which was 
released in plasma during attacks of acute pancreatitis was 
combined with a2-M, and that a2-M-bound kallikrein possessed 
little KF activity. The difference of the present results from 
Harpel's or the author's results on the interaction between a2-
M and KFE may be due to the difference in origin of the KFE. 
These results also raise the possibility that KFE from human 
skin may be a different enzyme from so-called kallikrein, i.e., 
plasma, urinary or pancreas kallikrein. 
In the present study, to elucidate the identity of KFE with 
human plasma, urinary or pancreas kallikrein, immunologic 
characterization of KFE was investigated and it was confmned 
that KFE is immunologically distinct from plasma, urinary or 
pancreas kallikrein. From all these results, although it is as-
sumed that KFE in human skin may be a new kallikrein which 
possesses high KF activity contrary to low esterolytic activity, 
there is another possibility that it may be a quite different 
enzyme from so-called kallikrein. 
In 1958, a KF activity and a kinin-like activity both produced 
by heating were found in human eccrine sweat by Fox and 
Hilton [1). On the contrary, Frewin et a!. [2] were not able to 
detect kinins in sweat, but did find KF activity in some sweat 
samples. In the present study, it could not also be confmned 
whether or not the KFE in human skin was the same glandular 
kallikrein originating in sweat or sebaceous glands as that of 
Fox and Hilton [1] or Frewin eta!. [2). In order to clarify the 
entity of KFE, further biochemical, biological or histo-patho-
logical studies will have to be carried out. 
The authors are grateful to Dr H. Sumi, Michael Reese ~~~ 
Center, and DrS. Takasugi, Hiroshima University, School of Medicme, 
for their valuable comments and suggestions. 
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ANNOUNCEMENT 
The Third National Congress of the Indonesian Society of Dermato-Venereology will be held on May 31-
June 4, 1980 in Medan, North Sumatra (Indonesia) . The Fourth Regional Conference of Dermatology which 
will be held on June 5-June 9, 1980 in Penang. For further information please contact: Dr. Marwali Harahap, 
Department of Dermatology, School of Medicine, University of North Sumatra, Rumah Sakit Umum Pusat, 
Jln., Prof. H . M. Hamin SH 47, Medan, Indonesia. 
